Objectives: Mutations in the GBA gene occur in 7% of patients with Parkinson disease (PD) and are a well-established susceptibility factor for PD, which is characterized by Lewy body disease (LBD) neuropathologic changes (LBDNCs). We sought to determine whether GBA influences risk of dementia with LBDNCs, Alzheimer disease (AD) neuropathologic changes (ADNCs), or both.
(pDLB), whereas many other cases show LBDNCs with coexistent high levels of ADNCs (LBD-AD). The pathophysiologic relationship among LBD-AD, pDLB, and PDD has not been delineated, and whether there is overlap of genetic risk factors among these disorders remains unclear.
Gaucher disease, the most common lysosomal storage disorder, results from a recessively inherited deficiency of glucocerebrosidase, which is encoded by the GBA gene. Heterozygous GBA mutation carriers have a 5-to 6-fold increased risk of developing PD. 2 The relationship between GBA mutations and DLB is less clear. Several small studies have observed a higher mutation frequency in patients with DLB than in controls, 3, 4 but interpretation of these results is limited by methodologic issues. Furthermore, one study reported an increased mutation frequency in patients with AD but without LBDNCs. 5 To address these issues, we screened for GBA in a large sample of subjects with neuropathologically determined AD, LBD-AD, and pDLB, and in controls without dementia. University of Washington). All controls were cognitively normal at study entry, as determined by a clinical consensus that considered both clinical history and neuropsychological testing. Controls remained free of cognitive impairment at their last evaluation, as indicated by a detailed clinical assessment (Rush ADC and Rush Memory and Aging Project), 9 a Cognitive Abilities Screening Instrument 10 score Ͼ85 (Group Health/University of Washington Alzheimer's Disease Patient Registry/Adult Changes in Thought Study), or a Clinical Dementia Rating score Ͻ1 and Mini-Mental State Examination score Ͼ26 (all other centers). None of the controls had a clinical diagnosis of a neurodegenerative disease, including PD. The controls consisted of 2 groups, one that underwent autopsy (n ϭ 267) and one in which the subjects were alive at the time the dataset was closed (n ϭ 124). All controls in the autopsied group underwent a clinical evaluation within 3 years of death.
Standard protocol approvals, registrations, and patient consents were obtained. All study procedures were approved by the institutional review boards at each participating site.
Neuropathologic classification. All autopsied cases underwent a standard histologic evaluation using hematoxylin & eosin, modified Bielschowsky, and thioflavine S methods. Immunostaining for LBDNCs was also performed on all autopsied cases using ␣-synuclein immunohistochemistry with antibody LB509 (1:50 to 1:400; Zymed, San Francisco, CA), as previously described. 11 Cases with questionable LB509 immunoreactivity were evaluated with a second antibody to nitrated ␣-synuclein (syn 303, 1:1,000). 12 A section from each of the following 5 regions was assessed for LBDNCs: medulla, substantia nigra, amygdala, cingulate gyrus, and frontal cortex. The only exception was that 3 regions (substantia nigra, cingulate gyrus, and frontal cortex) rather than 5 regions were assessed for LBDNCs in cases and controls from Rush University Medical Center. Braak staging 13 for neurofibrillary tangles and Consortium to Establish a Registry for Alzheimer's Disease plaque score 14 were determined using modified Bielschowsky-stained sections, tau immunohistochemistry (AT8, Endogen, 1:250), or both.
All subjects with dementia underwent autopsy and were neuropathologically classified as pDLB (n ϭ 80), LBD-AD (n ϭ 231), or AD (n ϭ 251) based on ADNCs and LBDNCs. AD was defined by the presence of high-level ADNCs (Braak stage IV, V, or VI and a Consortium to Establish a Registry for Alzheimer's Disease plaque score of "moderate" or "frequent") but no LBDNCs. LBD-AD was defined by the presence of both highlevel ADNCs and limbic or neocortical stage LBDNCs. 11 pDLB was defined by the presence of limbic or neocortical stage LBDNCs and no or low levels of ADNCs. Note that all cases with ADNCs that did not meet criteria for high level were classified as low level, and we did not include an "intermediate level" in order to maximize statistical power. The autopsied control group showed no evidence of LBDNCs or high-level ADNCs.
Mutational analysis. DNA was extracted from blood or brain tissue using standard methods. Because nearly 300 pathogenic mutations have been reported in patients with Gaucher disease, 15 our screening approach was designed to cover the entire GBA coding region. GBA was amplified with PCR in 3 fragments of 1.7 to 3.0 kilobases in length using primers that specifically amplify the functional gene but not the nearby pseudogene. All 11 GBA exons and intron-exon boundaries were then sequenced using the Applied Biosystems Big-Dye Terminator v3.1 Cycle Sequencing Kit on an ABI PRISM 3130 genetic analyzer (Applied Biosystems, Foster City, CA). Sequence data were base-Supplemental Data called, aligned, and scanned for variation using Mutation Surveyor (SoftGenetics, State College, PA). A mutation was considered "pathogenic" if it was previously reported in at least one patient with Gaucher disease. 15, 16 Fifty-five of the pDLB/ LBD-AD cases were previously screened for the 2 most common GBA mutations (N370S and L444P); these results have been published elsewhere. 4
Statistical analysis. Demographic and descriptive informa-
tion were summarized as means, standard deviations, and ranges for continuous measures and as proportions for discrete variables. Age and age at onset of dementia were compared among groups using analysis of variance. A Pearson 2 test was used to evaluate group differences in sex proportions.
The Fisher exact test was used to examine differences in GBA mutation frequency among groups. Multinomial logistic regression was used to test for association between GBA mutations and each of the 3 disease groups with controls as the reference. A test for a trend in the odds of carrying a mutation by disease group was performed using the score trend test. In this analysis, controls and AD cases were coded as 0, LBD-AD cases were coded as 1, and pDLB cases were coded as 2. All statistical analyses were conducted using STATA version 10 and a p value Ͻ0.05 was considered significant.
RESULTS
The demographic and clinical characteristics of the sample are shown in table 1. A substantially greater proportion of subjects with pDLB were male in comparison to the AD, LBD-AD, and control groups (overall 2 (3) ϭ 41.6, p Ͻ 0.001). There were no differences in age or age at onset among groups. Table 2 lists all GBA variants that were observed in the sample within exons or intronic splice sites, including 7 pathogenic mutations, 4 mutations of unknown significance, and 4 nonsynonymous polymorphisms. Note that 2 rare variants, K(Ϫ27)R and I(Ϫ20)V, were classified as polymorphisms because they have been observed to occur at a frequency of Ͼ5% in controls of African [K(Ϫ27)R; unpublished data] and Asian [I(Ϫ20)V] 17 ancestry. Twenty-five subjects were found to carry GBA mutations (patho-genic, n ϭ 19; unknown significance, n ϭ 6), and their neuropathologic findings are summarized in table e-1 on the Neurology ® Web site at www.neurology.org. Eighteen of these mutation carriers displayed LBDNCs (pDLB, n ϭ 7; LBD-AD, n ϭ 11), and 16 of the 18 cases had "neocortical" stage LBDNCs (figure). The remaining 2 cases had "limbic" stage LBDNCs 11 with involvement of the brainstem and cingulate gyrus but sparing of the neocortex. All cases were specifically examined for the pathologic changes previously described in 4 cases of Gaucher disease with parkinsonism and LBDNCs. 18 We observed neither "brainstem-type" Lewy bodies in the hippocampus nor severe neuronal loss and gliosis in the The GBA mutation frequencies in each group are presented in table 3. Among white subjects, 6 of the 79 cases with pDLB (7.6%) were heterozygous for a pathogenic GBA mutation, as were 8 of the 222 cases with LBD-AD (3.6%), 2 of the 243 cases with AD (0.8%), and 3 of the 381 controls (0.8%). There was an overall difference in the frequency of pathogenic GBA mutation carriers across groups (Fisher exact test, p ϭ 0.001). In comparison to controls, the carrier frequency was elevated in the pDLB ( p ϭ 0.001) and LBD-AD ( p ϭ 0.022) groups, but not in the AD group ( p ϭ 1.0).
In a logistic regression model adjusted for age and sex and limited to white subjects (table 4), pathogenic GBA mutations were associated with both pDLB (odds ratio [OR] ϭ 7.6; 95% confidence interval [CI] ϭ 1.8 -31.9; p ϭ 0.006) and LBD-AD (OR ϭ 4.6; 95% CI ϭ 1.2-17.6; p ϭ 0.025), but not AD (OR ϭ 1.1; 95% CI ϭ 0.2-6.6; p ϭ 0.92). Inspection of the ORs suggested that individuals with LBD-AD might have a mutation carrier risk intermediate between the pDLB and AD/control groups. We assessed this hypothesis using a trend test. Given that the frequency of GBA mutations in controls and AD cases was nearly identical, for the purposes of this test, the controls and AD cases were collapsed into a single group. The results indicated an increased likelihood of carrying a GBA mutation across groups in the following direction: control/AD Ͻ LBD-AD Ͻ pDLB ( 2 [1] ϭ 19.3; p ϭ 1.1 ϫ 10 Ϫ5 ).
DISCUSSION
Our results are novel in that they suggest that GBA conveys a higher risk for pDLB than for LBD-AD. The observed frequency of pathogenic mutations in the pDLB group (7.6%) was very similar to the 7% frequency reported in a multicenter analysis of 1,883 patients with PD in whom GBA was fully sequenced. 2 In contrast to another report, 5 we did not find differences in the proportion of GBA mutation carriers between controls and patients with AD. pDLB and PDD are neuropathologically indistinguishable from one another 19 whereas clinically, pDLB more closely resembles LBD-AD. Also, in contrast to LBD-AD, both pDLB and PDD exhibit a strong male predominance. 20, 21 The degree to which genetic factors have a role in shaping the similarities and differences among these 3 clinicopathologic entities is not well understood, in part because very few genetic studies have made a distinction between pDLB and LBD-AD. Our findings address this gap in knowledge and begin to differentiate the "genetic profiles" of PDD, pDLB, and LBD-AD. Taken together with previous work, 2 our data suggest that in terms of the risk conveyed by GBA mutations, pDLB and PDD overlap more closely with one another than with LBD-AD. Whether this same pattern will prove to be true for other susceptibility genes remains to be determined.
Five studies [3] [4] [5] 22, 23 have previously investigated the association between GBA mutations and DLB, and 2 of these studies have reported a significantly higher mutation frequency in the DLB group than in the matched controls. 4, 5 The observed DLB mutation carrier frequency varied several-fold across studies, from 27 of 95 cases (28%) 5 to 3 of 57 cases (3.5%). 4 Furthermore, one study 5 reported an increased GBA mutation frequency of 10% in 60 cases with a neuropathologic diagnosis of AD and without LBDNCs. There are several factors that might explain these seemingly discrepant findings. Two of the studies lacked sufficient clinical information to exclude all cases with a clinical diagnosis of PD. 5, 23 Without making this distinction, one cannot accurately estimate separate mutation frequencies for PD and DLB. 1 Two of the studies did not include a matched control group and instead referenced previously published mutation frequencies in controls. 3, 23 All previous studies had more modest sample sizes than the current study and thus only had sufficient power to detect large effects at the expected allele frequencies.
One study assessed only the 2 most common pathogenic GBA mutations (N370S and L444P) rather than screening the entire coding region. 4 Thus, some other pathogenic mutations were likely missed. In one study, the reported mutation frequency included rare variants of unknown functional significance and low-frequency polymorphisms. 5 Finally, GBA mutation frequencies are substantially higher in Ashkenazi Jews, 24 but none of the prior studies reported the proportion of subjects with Ashkenazi Jewish ancestry in the sample.
Our study had several strengths. The sample was large and was well characterized both clinically and neuropathologically. Importantly, all subjects with pDLB and LBD-AD had clinically documented dementia at onset rather than parkinsonism, allowing for exclusion of patients with PDD. We included a matched control group in which all subjects were screened for cognitive impairment and more than half underwent autopsy. All pathologic examinations for LBD were made using the same methods (by J.L., R.H., T.M., J.S., and P.N.). Finally, we comprehensively screened all GBA exons rather than selectively genotyping a subset of mutations. Our study also had limitations. Because the majority of subjects included in this clinicopathologic study died before the publication of the clinical criteria for DLB, we were unable to fully apply these criteria retrospectively, in particular the "fluctuating cognition" and "REM sleep behavior disorder" features. 1 Also, as in previous studies, we did not collect information on the presence of Ashkenazi Jewish ancestry in all subjects and thus we cannot entirely exclude the possibility of unrecognized population structure in our dataset.
In a neuropathologic study of 14 patients with Gaucher disease, 18 only the 4 cases that displayed clinical parkinsonism and dementia had LBDNCs. In all cases, the authors noted hippocampal and neocortical gliosis, and they also observed marked neuronal loss in a subset of cases with phenotypically severe type II and III disease. The LBDNCs were unusual in that "brainstem-type" Lewy bodies were seen in the hippocampus. We specifically evaluated the GBA mutation carriers identified in our study for these pathologic changes and they were not observed. However, we did observe severe and anatomically diffuse LBDNCs in the majority of GBA mutation carriers, including ␣-synuclein immunopositive inclusions in hippocampal neurons. We suspect that the pathologic differences observed between the Gaucher disease cases with parkinsonism and our patients with pDLB and LBD-AD might be attributable to a gene dosage effect in that the Gaucher disease patients had 2 alleles with reduced or absent function whereas our patients had only 1.
Although findings from this and other casecontrol studies indicate an association between GBA mutations and LBD, the molecular mechanism by which dysfunction of the gene leads to LBDNCs and neurodegeneration has not been fully elucidated. However, recent in vivo and in vitro experiments indicate that GBA mutations promote aggregation of ␣-synuclein 25 and enhance ␣-synuclein-mediated neurotoxicity, 26 thus providing the first evidence directly linking alteration of glucocerebrosidase function with synucleinopathy.
Despite recent progress on the role of GBA in LBD, several critical questions remain to be answered. For example, although GBA mutations are a strong risk factor for LBD, most GBA carriers remain asymptomatic. Also, for those mutation carriers who do become symptomatic, it is not clear why some present with dementia at onset Table 4 Association of GBA mutations with dementia by group (pDLB or LBD-AD) whereas others present with parkinsonism (PD). It is likely that genetic and environmental factors modify the expression of GBA-related neurodegeneration. This hypothesis should be tested with large-scale genetic association studies, which incorporate careful clinicopathologic characterization and collection of detailed environmental exposure data. Familybased studies might be particularly fruitful. Although such endeavors will be challenging, the identification of major modifying factors for GBAinduced synucleinopathies could substantially accelerate progress in developing improved treatment strategies for LBD.
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